CY1112509T1 - Αγωγη απισχνανσης των μυων με επιλεκτικους τροποποιητες του υποδοχεα των ανδρογονων - Google Patents

Αγωγη απισχνανσης των μυων με επιλεκτικους τροποποιητες του υποδοχεα των ανδρογονων

Info

Publication number
CY1112509T1
CY1112509T1 CY20121100004T CY121100004T CY1112509T1 CY 1112509 T1 CY1112509 T1 CY 1112509T1 CY 20121100004 T CY20121100004 T CY 20121100004T CY 121100004 T CY121100004 T CY 121100004T CY 1112509 T1 CY1112509 T1 CY 1112509T1
Authority
CY
Cyprus
Prior art keywords
muscle
disconnection
training
androgen receptor
muscle wasting
Prior art date
Application number
CY20121100004T
Other languages
English (en)
Inventor
Mitchell S Steiner
Karen A Veverka
James T Dalton
Duane D Miller
Original Assignee
Gtx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx, Inc. filed Critical Gtx, Inc.
Publication of CY1112509T1 publication Critical patent/CY1112509T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Αυτή η εφεύρεση παρέχει: μέθοδο αγωγής υποκειμένου που υποφέρει από διαταραχή απίσχνανσης των μυών • μέθοδο πρόληψης διαταραχής απίσχνανσης των μυών σε ένα υποκείμενο• μέθοδο αγωγής, πρόληψης, καταστολής, αναστολής ή μείωσης της απώλειας των μυών σε ένα υποκείμενο που υποφέρει από διαταραχή απίσχνανσης των μυών• μέθοδο αγωγής, πρόληψης, αναστολής, μείωσης ή καταστολής της απίσχνανσης των μυών σε ένα υποκείμενο που υποφέρει από διαταραχή απίσχνανσης των μυών• και/ή μέθοδο αγωγής, πρόληψης αναστολής, μείωσης ή καταστολής του καταβολισμού των πρωτεϊνών των μυών σε ένα υποκείμενο που υποφέρει από διαταραχή απίσχνανσης των μυών, μέσω της χορήγησης στο υποκείμενο επιλεκτικού τροποποιητή του υποδοχέα των ανδρογόνων (SARM) και/ή του αναλόγου, παραγώγου, ισομερούς, μεταβολίτη, φαρμακευτικώς αποδεκτού άλατος φαρμακευτικού προϊόντος, ένυδρου άλατος, Ν-οξειδίου αυτού ή του οποιουδήποτε συνδυασμού εξ αυτών, ως περιγράφεται εις το παρόν.
CY20121100004T 2001-12-06 2012-01-04 Αγωγη απισχνανσης των μυων με επιλεκτικους τροποποιητες του υποδοχεα των ανδρογονων CY1112509T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33618501P 2001-12-06 2001-12-06
EP02802565A EP1463497B1 (en) 2001-12-06 2002-12-05 Treating muscle wasting with selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
CY1112509T1 true CY1112509T1 (el) 2015-12-09

Family

ID=23314937

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100004T CY1112509T1 (el) 2001-12-06 2012-01-04 Αγωγη απισχνανσης των μυων με επιλεκτικους τροποποιητες του υποδοχεα των ανδρογονων

Country Status (21)

Country Link
US (1) US7547728B2 (el)
EP (2) EP2289503B1 (el)
JP (2) JP4605557B2 (el)
KR (1) KR100767317B1 (el)
CN (1) CN1617715B (el)
AT (1) ATE526959T1 (el)
AU (1) AU2002364949C1 (el)
BR (1) BR0215115A (el)
CA (1) CA2469340A1 (el)
CY (1) CY1112509T1 (el)
DK (1) DK1463497T3 (el)
EA (1) EA007921B1 (el)
ES (1) ES2372929T3 (el)
GE (1) GEP20063984B (el)
HK (1) HK1068102A1 (el)
HR (1) HRP20040588A2 (el)
IL (2) IL162340A0 (el)
MX (1) MXPA04005519A (el)
PT (1) PT1463497E (el)
TW (1) TWI339118B (el)
WO (1) WO2003049675A2 (el)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) * 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
WO2003049675A2 (en) * 2001-12-06 2003-06-19 Gtx, Inc. Treating muscle wasting with selective androgen receptor modulators
ATE518537T1 (de) 2002-02-07 2011-08-15 Univ Tennessee Res Foundation Selective androgen-rezeptor-modulatoren (sarms) für die behandlung der benignen prostatahyperplasie
EP2266577B8 (en) * 2002-02-28 2015-01-21 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
EA013818B1 (ru) * 2002-02-28 2010-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Полизамещённые селективные модуляторы рецептора андрогенов и способы их применения
KR101088352B1 (ko) 2002-02-28 2011-11-30 유니버시티 오브 테네시 리서치 파운데이션 다치환된 선택적 안드로겐 수용체 조절자 및 이를 사용하는 방법
EP1543722B1 (en) * 2002-08-19 2015-04-15 Nagoya Industrial Science Research Institute Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy
CA2502209A1 (en) * 2002-10-15 2004-04-29 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
EP1558233A2 (en) * 2002-10-16 2005-08-03 GTX, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
DE602004026583D1 (de) * 2003-06-27 2010-05-27 Orion Corp Als androgenrezeptormodulatoren geeignete propionamidderivate
CN100462353C (zh) * 2003-06-27 2009-02-18 奥赖恩公司 用作雄激素受体调节剂的丙酰胺衍生物
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
JP2007508386A (ja) * 2003-10-14 2007-04-05 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体調節剤による骨関連疾患の治療
EP1631540A4 (en) * 2003-12-16 2006-10-04 Gtx Inc PRODRUGS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD OF USE THEREOF
EP1737813A1 (en) * 2004-04-13 2007-01-03 Warner-Lambert Company LLC Androgen modulators
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
EP2289872B1 (en) * 2004-06-07 2017-08-02 University of Tennessee Research Foundation Medical uses of a selective androgen receptor modulator
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
ATE485300T1 (de) 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
US7655700B2 (en) * 2005-08-25 2010-02-02 Michigan State University Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles
KR101388087B1 (ko) * 2005-08-31 2014-04-25 유니버시티 오브 테네시 리서치 파운데이션 선택적 안드로겐 수용체 조절제를 이용한 신장 질환, 화상,부상 및 척수 손상의 치료 방법
WO2008008433A2 (en) * 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
AU2007287070C1 (en) 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
DK2176220T3 (da) 2007-08-07 2013-06-10 Takeda Pharmaceutical Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
DK2205552T3 (en) * 2007-09-11 2018-04-16 Gtx Inc CRYSTALLINIC POLYMORPH OF THE SELECTIVE ANDROGEN MODULATORS (R) - OR (S) -N- (4-CYANO-3- (TRIFLUOROMETHYL) PHENYL) -3- (4-CYANOPHENOXY) -2-HYDROXY-2-METHYLPROPANAMIDE
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
AU2011255495A1 (en) 2010-05-20 2012-12-06 The United States Of America, As Represented By The Secretary Of The Department Of Veterans Affairs Methods for inhibiting muscle atrophy
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
US8395552B2 (en) 2010-11-23 2013-03-12 Metamagnetics, Inc. Antenna module having reduced size, high gain, and increased power efficiency
CN106822153B (zh) 2011-06-06 2019-12-17 爱荷华大学研究基金会 用于抑制肌萎缩的方法
WO2013078372A1 (en) * 2011-11-23 2013-05-30 University Of Iowa Research Foundation Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy
EP2834216A1 (en) * 2012-04-04 2015-02-11 Catylix Inc. Selective androgen receptor modulators
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
RU2717835C2 (ru) 2012-07-13 2020-03-26 Джи Ти Икс, ИНК. Способ лечения андроген-рецептор(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов (sarm)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
JP2015071549A (ja) * 2013-10-02 2015-04-16 株式会社ファンケル アトロジン−１抑制剤
WO2015108988A2 (en) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
MX2017004819A (es) * 2014-10-16 2018-06-12 Gtx Inc Metodos de tratamiento de transtornos urológicos usando sarm.
KR101919081B1 (ko) * 2017-05-11 2018-11-16 (주)녹십자웰빙 인간 태반 추출물을 유효성분으로 포함하는 근 위축증 또는 근육감소증의 예방 또는 치료용 및 근육 기능 개선용 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) * 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
US4336505A (en) * 1980-07-14 1982-06-22 John Fluke Mfg. Co., Inc. Controlled frequency signal source apparatus including a feedback path for the reduction of phase noise
JPS57171904A (en) * 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
EP0100172B1 (en) * 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US4633025A (en) 1985-04-15 1986-12-30 Miles Laboratories, Inc. Method for preparing (+)R-2-methyl-hexane-1,2-diol
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5847076A (en) * 1993-05-20 1998-12-08 Board Of Regents, The University Of Texas System Regulators of the proteasome
JPH09508125A (ja) 1994-01-21 1997-08-19 セプラコー，インコーポレイテッド 光学的純正ｒ−（−）−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成
US5609849A (en) * 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6995284B2 (en) * 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6492554B2 (en) * 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6160011A (en) * 1997-05-30 2000-12-12 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en) 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
WO2001027622A1 (en) 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
CN1409702A (zh) 1999-10-19 2003-04-09 诺贝克斯公司 不对称合成Casodex、其衍生物及其中间体的对映体的方法
BR0015124A (pt) 1999-10-27 2002-07-02 Nobex Corp Método de preparação de um enanciÈmero substancialmente puro
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
EP1299094A2 (en) 2000-06-28 2003-04-09 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
EP1705174A1 (en) * 2000-08-24 2006-09-27 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
WO2003049675A2 (en) * 2001-12-06 2003-06-19 Gtx, Inc. Treating muscle wasting with selective androgen receptor modulators
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä

Also Published As

Publication number Publication date
EP1463497A4 (en) 2007-11-14
AU2002364949C1 (en) 2008-05-29
IL162340A (en) 2013-09-30
CA2469340A1 (en) 2003-06-19
HRP20040588A2 (en) 2004-10-31
EP2289503A3 (en) 2011-04-06
EP2289503B1 (en) 2016-06-29
JP2005516002A (ja) 2005-06-02
TW200410674A (en) 2004-07-01
IL162340A0 (en) 2005-11-20
US7547728B2 (en) 2009-06-16
KR20050044714A (ko) 2005-05-12
HK1068102A1 (en) 2005-04-22
TWI339118B (en) 2011-03-21
JP2010254707A (ja) 2010-11-11
JP4605557B2 (ja) 2011-01-05
EP1463497B1 (en) 2011-10-05
PT1463497E (pt) 2011-12-20
GEP20063984B (en) 2006-12-11
MXPA04005519A (es) 2005-06-20
CN1617715A (zh) 2005-05-18
ATE526959T1 (de) 2011-10-15
EP1463497A2 (en) 2004-10-06
US20040087557A1 (en) 2004-05-06
AU2002364949A1 (en) 2003-06-23
EA007921B1 (ru) 2007-02-27
DK1463497T3 (da) 2012-01-30
BR0215115A (pt) 2005-04-19
EA200400774A1 (ru) 2004-12-30
WO2003049675A2 (en) 2003-06-19
EP2289503A2 (en) 2011-03-02
WO2003049675A3 (en) 2004-04-01
ES2372929T3 (es) 2012-01-27
KR100767317B1 (ko) 2007-10-17
CN1617715B (zh) 2010-05-12

Similar Documents

Publication Publication Date Title
CY1112509T1 (el) Αγωγη απισχνανσης των μυων με επιλεκτικους τροποποιητες του υποδοχεα των ανδρογονων
NO20032892L (no) 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
DK1429761T3 (da) Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
BR0209511B1 (pt) composiÇço herbicida sinergÍstica, e, mÉtodo para controlar vegetaÇço indesejÁvel.
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
SE9900100D0 (sv) New compounds
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
NO20041170L (no) 4,5-dihydro-1H pyrazolderivater med kraftig CB1 antagonistisk aktivitet
DE10297014T5 (de) Mehrdimensionaler Mehr-Ebenen-Inhalte-Schutz
TW200724033A (en) Anthranilamide arthropodicide treatment
DE60216184D1 (de) Einstückiges Leitringsegment
DK1173484T3 (da) Behandling af fibrose ved antagonisme mellem IL-13 og IL-13-receptorkæder
MXPA03007140A (es) Derivados de carbolina.
ZA200200619B (en) Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof.
ATE294799T1 (de) Hydrochloride kondensierter heterozyklen
DE60216233D1 (en) Carbolinderivate
GC0000155A (en) 6-Hydroxy-indazole derivatives for treating glaucoma.
DK1267847T3 (da) 5HT2-antagonist til regulering af IOP og behandling af glaucom
MY122838A (en) Treating allergic and inflammatory conditions
DK3103443T3 (da) Fremgangsmåde til behandling af primær søvnforstyrrelse
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
TR200705146T1 (tr) Monoamin Yükselmesinin Engellenmesi
DE60333581D1 (de) Bewuchsverhinderndes dispersionsmittel
ITRM20020308A0 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.
DK1459751T3 (da) (S,S)reboxetin til behandling af migrænehovedpine